INTRODUCTION
Large-scale whole exome sequencing projects such as the Deciphering Developmental Disorders (DDD) project have led to the discovery of a number of new genes underlying developmental disorders. 1 2 A reverse-genetics approach has proven particularly important for the discovery of disorders such as Bainbridge-Ropers syndrome (BRPS), whose main clinical features are non-specific, especially when looked at in isolation or with a small number of patients. De novo mutation status is the first clue to potential pathogenicity of a given variant, and such mutations are known to constitute a significant proportion of the underlying causes of moderate and severe intellectual disability (ID).
3
ASXL1, ASXL2 and ASXL3 are human homologues of the Drosophila additional sex combs (ASX) gene that encode putative polycomb proteins and are likely to act as histone methyltransferases in complexes with other proteins. 4 Polycomb group proteins are implicated in embryogenesis and carcinogenesis through transcriptional regulation of target genes; the ASXL1 gene is thought to be one of the most frequently mutated genes in malignant myeloid diseases; ASXL is a scaffold protein interacting with methyltransferases and additional proteins of the epigenetic machinery. 5 6 Truncating mutations in ASXL1 have been reported in association with Bohring-Opitz syndrome (BOS) which has phenotypic overlap with BRPS. 7 More recently, truncating mutations in ASXL2 were reported in association with a newly recognisable clinical phenotype. 8 Srivastava et al 9 showed that additional sex combs like 3 (ASXL3) interacts with BAP1, a hydrolase that removes mono-ubiquitin from histone H2A lysine 119 (H2AK119Ub1) as a component of the polycomb repressive deubiquitination (PR-DUB) complex. The authors observed a significant increase in H2AK119Ub1 in ASXL3 patient fibroblasts, highlighting an important functional role for ASXL3 in PR-DUB mediated deubiquitination. Transcriptome analysis revealed >500 genes differentially expressed in ASXL3 patient fibroblasts relative to controls, and these genes were enriched for those involved with molecular processes, impacting transcriptional regulation, development and proliferation.
ASXL3 is expressed in tissues similar to ASXL1 including brain, spinal cord, kidney, liver and bone marrow, but at a lower level. 10 The high correlation of expression patterns between ASXL1 and ASXL3 may account for some of the shared phenotypic features.
Heterozygous, de novo loss-of-function mutations in ASXL3, underlying the BRPS (OMIM #615485), have been described in nine individuals to date. 9 11-13 The major phenotypic features described in the majority of patients so far include failure to thrive, global developmental delay, feeding problems, hypotonia, dysmorphic features, profound speech delay and ID. Here, we present genetic and phenotypic information on 12 previously unreported individuals with de novo truncating mutations in ASXL3, all of which were detected via trio exome sequencing carried out by the DDD project. Additional clinical features of BRPS are likely to emerge with the identification of additional patients through such large-scale exome sequencing projects as described here.
METHODS

Exome sequencing
In all 12 individuals identified via the DDD study, trio-based exome sequencing was performed on the affected individual and their parents, as previously described by Wright et al. 2 Each affected individual has also had a high-resolution analysis for copy number abnormalities, using array-based comparative genomic hybridisation (aCGH). Putative de novo mutations were identified from exome data using DeNovoGear software as described by Ramu et al 3 and were validated using targeted Sanger sequencing. Mutation nomenclature is according to Human Genome Variation Society (HGVS) recommendations (http://varnomen.hgvs. org/), and is based on reference transcript NM_030632.2.
Patient ascertainment
All 12 individuals were recruited via UK National Health Service (NHS) Regional Genetics Services onto the DDD project (http://www.ddduk.org). As part of that study, patient and parental samples receive array CGH and exome sequencing analysis, and findings of potential clinical significance are reported back to recruiting clinical geneticists. Any significant findings are usually validated by an accredited UK NHS diagnostic genetics laboratory before being reported to patients and their families; mutations described in this paper have been validated as such. Patient phenotype information was provided to the authors via clinical geneticists from several UK NHS genetics services. See table 1 for a summary of the clinical and molecular findings.
RESULTS
ASXL3 mutations
Previously reported truncating ASXL3 mutations cluster mainly within the 5 9 which could be considered as a distinct mutation cluster region, extending between codons 1045 and 1444. All these mutations are publicly available on http://www.ddduk.org.
Patient phenotypes Antenatal history and birth
Polyhydramnios and concerns regarding poor growth was noted in 1/12, but otherwise unremarkable. For 9/12 patients, a caesarean section was performed, mostly due to breech presentation. All 12 patients had an average birth weight (BW), and apart from 4/12 patients who were admitted to the neonatal unit for respiratory difficulties/apnoea, in the remainder neonatal period was uneventful.
Feeding problems
Consistent with previous reports, 9/12 patients were reported to have significant feeding problems, often including gastrooesophageal reflux, requiring intervention in the form of nasogastric tube feeding, fundoplication. The majority were described as having failure to gain weight with poor appetite.
Growth
Patients reported here had consistent poor growth, with weight and height below the 0.4th centile and relative microcephaly (7/ 12) . This is in keeping with the previously reported literature.
Craniofacial features
Nine out of twelve patients have a high-arched palate, distinctive facial dysmorphism, as described below (figure 1). Figure 1A -J shows the facial features of patients recruited to the study at varying ages: 10/12 had downslanting palpebral fissures and 2 had upslanting palpebral fissures; both have previously been reported, but downslanting seems to be more common. A long, tubular nose with a prominent nasal bridge is apparent in most patients. Most of the individuals have a broad nasal tip with low columella. The mouth is wide with full (everted) lower lip. Hypertelorism, a narrow head shape with prominent forehead, 'pencilled' and/or high-arched eyebrows and crowded teeth were also common features.
Dysmorphic features
Other significant features 11/12 patients had significant hypotonia; 7/12 had strabismus of varying severity. Three patients had seizures, previously reported in two other ASXL3 patients. Patient 2 had scoliosis requiring surgery. Three patients had arachnodactyly, not previously reported in any ASXL3 patients. Three out of twelve patients appear to have a Marfanoid habitus with arachnodactyly, tall stature, pes planus and scoliosis. 
Intellectual disability
The level of ID ranged from moderate to profound, but more likely at the severe end of the spectrum. All patients had ID of varying degree. Most were very delayed in walking unassisted, and two remained entirely non-ambulant. Nine of twelve patients were non-verbal, including Patient 2 at 22 years of age. Nine of twelve patients had either formally diagnosed autism or autism spectrum disorder (ASD), or were described as having autistic features. Three patients exhibited hand-flapping and rocking. 11/12 patients were in a special needs school, requiring significant help.
Relevant negative findings
Seizures do not appear to be a major feature, seen in only 3/12 patients and generally well-controlled absence seizures; MRI brain imaging only showed non-specific features with white matter changes (3/12) and vermis hypoplasia (1/12), which is relevant given the significance of ID in this cohort of patients.
DISCUSSION
The recently described BRPS (OMIM # 615485), associated with de novo truncating mutations in the ASXL3 gene (OMIM * 615115), shows phenotypic overlap with BOS, which is associated with de novo truncating mutations in ASXL1 (OMIM * 612990). BOS (OMIM # 605039) is characterised by distinct craniofacial features and posture, severe ID, feeding problems, small size at birth and failure to thrive. Bainbridge et al 11 reported a series of four unrelated probands with de novo, heterozygous, truncating mutations in ASXL3, sharing similar phenotypes, including severe feeding difficulties, failure to thrive and neurological abnormalities with significant developmental delay. More recently, truncating mutations in ASXL2 were reported as being associated with a newly recognisable syndrome with overlapping features to BOS and BRPS. 8 In this report, the authors described six unrelated patients with de novo truncating mutations in ASXL2 with shared clinical features including ID, macrocephaly, distinct facies, facial naevi, feeding difficulties and hypotonia.
Comparison of patients reported in this with BRPS shows the facial dysmorphism to be more similar to BOS with macrocephaly, arched eyebrows, synophrys and facial naevi rather than with BRPS. Other distinguishing features included macrocephaly, congenital heart disease, structural brain malformations and seizures in these patients, which differ with the BRPS cohort. However, there are emerging similarities within this group of conditions, including hypotonia, feeding difficulties and ID, which will become more apparent as more patients are reported with ASXL2 mutations. To date, there have been fewer than 10 reported patients with de novo truncating ASXL3 mutations. Emerging similarities include distinctive craniofacial features with arched eyebrows, prominent forehead, high-arched palate, hypertelorism with downslanting palpebral fissures; significant feeding difficulties needing support; profound/severe ID; emerging behavioural phenotype consisting of autistic traits, hand-flapping, rocking, aggressive behaviour, sleep issues with absent/poor speech. Table 1 provides a comprehensive summary of reported features in this cohort: predominant features in the phenotype are normal pregnancy, higher incidence of caesarean section due to breech presentation, relative microcephaly, significant feeding difficulties, facial dysmorphism , high-arched palate, strabismus, hypotonia, skeletal features including a Marfanoid habitus (especially in the older patients), severe ID with poor/absent speech, autistic traits, need for special education. Seizures, structural malformations of internal organs including the brain and kidneys do not appear to be a predominant part of their phenotype. However, this is likely to be revised/expanded as more patients are described with BRPS.
There is a wide age range (4-22 years), this being the first report of older patients with BRPS. The older patients in this cohort all have moderate-to-severe ID, autistic features, attended a special needs school and are in assisted living. Seizures are a component but not a predominant part of their phenotype, and they do not appear to have any major structural associations with this diagnosis as they have grown older. The behavioural phenotype appears to be in keeping with other severe developmental disorders with absent/poor speech, periods of agitation, frustration and poor sleep.
Though BRPS is likely to remain a challenging syndrome to recognise clinically, this cohort of patients has enabled further delineation and expansion of the phenotype. Results of analysis of the first several thousand patient trios within the DDD project suggest that de novo ASXL3 mutations are among the more common underlying causes of disease within the DDD cohort (at the time of writing, ASXL3 ranks number 12 out of the top 20 genes in which a pathogenic de novo mutation has been found), and therefore it is expected that there will be many more patients with BRPS diagnosed in the near future, further defining the associated clinical spectrum.
Our cohort has also firmly established a second, 3 0 mutational cluster region (MCR) within ASXL3 which may be of significance to disease mechanism. With regard to this, an ASXL3 mRNA transcript carrying the c.1448dupT truncating mutation has previously been shown to be prone to non-sense mediated decay (NMD), with the resultant reduction in the expression of ASXL3.
6 Consistent with previous reports and consistent with this disease mechanism, the cohort of patients described here do not show a correlation between phenotypic features or severity and mutation position. It has previously been noted that several truncating mutations in ASXL3 are described in databases composed of sequence variants from phenotypically normal individuals (see figure 2) . To date, there are four such mutations within the ExAC dataset, each identified within only one individual within the dataset, and they occur at both 5 0 to the original 5 0 MCR and 3 0 to the new 3 0 cluster region, and also in between the two cluster regions. The explanation for these mutations is as yet uncertain. We have also been able to collect phenotypic data from several patients with previously unreported mis-sense variants in ASXL3 (including p.Ser86Ala, p.Lys1026Asn, p.Arg933Trp and p.Ser720Cys). However, in each case, the variants were inherited from clinically unaffected parents, and the patients had a very dissimilar presentation in comparison with the clinical presentation associated with ASXL3 loss-of-function mutations. Without further investigation, it cannot be ruled out that these variants are of clinical significance; however, it is unlikely that they are the sole cause of the phenotype observed in these patients. It is possible that they represent rare polymorphisms. In support of this, all of these variants are found, although at low frequency, within healthy control populations (Exome Aggregation Consortium (ExAC), Cambridge, Massachusetts, URL: http:// exac.broadinstitute.org).
Ropers and Wienker, 14 previously highlighted the presence of truncating mutations in ASXL3 and several other dominant genes for ID or related disorders, within healthy control populations, suggesting the possibility of incomplete penetrance for truncating mutations within these genes. This included ASXL1, for which 56 such mutations were found within the ExAC dataset.
While it cannot be entirely ruled out that truncating ASXL3 mutations exhibit incomplete penetrance, the number of such mutations (four) found within the ExAC data is still relatively small compared with ASXL1 and the other genes examined, and the list of reported patients with ASXL3 truncating mutations that have a BRPS-consistent phenotype is growing.
Therefore, it seems reasonable that all four of these ASXL3 mutations may be accounted for by the various other explanations that Ropers put forward, for example, two of the mutations occur at the extreme 3 0 end of the gene, and may therefore escape NMD, retaining protein activity. Bainbridge et al 11 suggested that mutations may arise postzygotically or during later embryogenesis, and thus the phenotypic variability or incomplete penetrance may be explained by mosaicism. 11 With the increasingly wider access of high read-depth exome sequencing for genetic diagnosis of children with developmental disorders, it seems likely that this question will eventually be answered as more data emerge.
CONCLUSIONS
In this series, we report 12 patients with ASXL3 loss-of-function de novo variant and expand the phenotype of BRPS. New specific associated clinical features have become apparent, such as hypotonia, Marfanoid habitus and arachnodactyly. This cohort is consistent with previously reported patients with regard to the facial features and also confirms pertinent negative features such as lack of significant findings on brain imaging and lack of seizures. This research further reiterates the power of whole exome studies in conjunction with a detailed clinical phenotype in providing an explanation for our patients' difficulties and a unifying diagnosis for their concerns. Correction Notice This article has been corrected since it published online first. The photograph of patient 5 has been updated in Figure 1 and Figure 3E . Edits have been made to some of the data in table 1 and the 'Intellectual disability' section has been edited to accurately reflect the number of patients attending a special school (11/12) and the degree of ID in the patients. Figure legend for Figure  3 has been added 'Frontal and profile images of patients with ASXL3 variants at varying ages'. K Chandler affiliation is 9,10. D T Pilz middle initial has been updated. The number for hypotonia has been updated in the abstract results (11/ 12) . In Table 1 , edits have been made as follows for Patient 3: column: weight 25th centile and 'No' for hypotonia with R/V across for 'Hypotonia' reading 11/12.
